Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | SPR | P35270 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 9/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806341 | 0.91 | HSD11B1 (0.60) | HSD11B1SPRUSP30KDM5ADRD4 | |
| SCHEMBL16565554 | 0.86 | ACHE (0.56) | HSD11B1SPRDRD4DRD2SCD5 | |
| SCHEMBL14781405 | 0.86 | HSD11B1 (0.52) | HSD11B1SPRUSP30KDM5ADRD4 | |
| SCHEMBL15755669 | 0.84 | HSD11B1 (0.51) | HSD11B1SPRUSP30KDM5ADRD4 | |
| SCHEMBL1740411 | 0.83 | HSD11B1 (0.49) | HSD11B1SPRUSP30KDM5ASCD5 | |
| SCHEMBL31228434 | 0.83 | HSD11B1 (0.49) | HSD11B1SPRUSP30KDM5ASCD5 | |
| SCHEMBL6347014 | 0.83 | HSD11B1 (0.53) | HSD11B1SPRUSP30KDM5ADRD4 | |
| SCHEMBL19659044 | 0.82 | DRD4 (0.50) | HSD11B1SPRUSP30KDM5ADRD4 | |
| SCHEMBL19652164 | 0.82 | KDM5A (0.54) | HSD11B1SPRUSP30KDM5ADRD4 | |
| SCHEMBL29640084 | 0.80 | HSD11B1 (0.59) | HSD11B1SPRUSP30KDM5ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391901-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-11-28 | — | — | US | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3006438-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2099454-A2 | AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS | Abbott Laboratories (US) | 2009-09-16 | — | — | EP | disclosed |
| CN-101534824-A | Aminopyrrolidines as chemokine receptor antagonists | ABBOTT LAB (US) | 2009-09-16 | — | — | CN | disclosed |
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008060621-A2 | AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | PFIZER INC. | 2007-10-25 | — | — | US | disclosed |
| EP-1784408-A1 | TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021882-A1 | TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | HSD11B1 251/4885SPR 1000/4885USP30 4814/4885 |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | DRD2, DRD4, DRD1 | HSD11B1 829/4885SPR 1980/4885USP30 3702/4885 |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | AVPR2, AVPR1A, AVPR1B | HSD11B1 577/4885SPR 970/4885USP30 3484/4885 |
| US-20240391901-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF | FAAH, FAAH2, FAH | HSD11B1 152/4885SPR 2803/4885USP30 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.